8-K filing — Whitehawk Therapeutics, Inc. (WHWK)
Filed: 2026-08-06 AccNo: 0001193125-26-337069 Size: 629 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Whitehawk Therapeutics Collaborates With Biocytogen To Develop Bispecific Antibody-Drug Conjugates
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 7, 2026, 12:04 PM
- Checked
- Jul 7, 2026, 12:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Whitehawk Therapeutics Q2 EPS $(0.20) Beats $(0.30) Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 73.68 percent increase over losses of $(0.76) per
Read original at benzingaLeerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9
Read original at benzinga